Background: Low magnesium levels are associated with an elevated risk of stroke. In this study, we investigated the association between magnesium levels on hospital admission and in-hospital mortality in acute ischemic stroke (AIS) patients. Methods: A total of 2,485 AIS patients, enrolled from December 2013 to May 2014 across 22 hospitals in Suzhou city, were included in this study. The patients were divided into 4 groups according to their level of admission magnesium: Q1 (<0.82 mmol/L), Q2 (0.82-0.89 mmol/L), Q3 (0.89-0.98 mmol/L), and Q4 (≥0.98 mmol/L). Cox proportional hazard model was used to estimate the effect of magnesium on all-cause in-hospital mortality in AIS patients. Results: During hospitalization, 92 patients (3.7%) died from all causes. The lowest serum magnesium level (Q1) was associated with a 2.66-fold increase in the risk of in-hospital mortality in comparison to Q4 (hazard ratio [HR] 2.66; 95% CI 1.55-4.56; p-trend < 0.001). After adjusting for age, sex, time from onset to hospital admission, baseline National Institutes of Health Stroke Scale score, and other potential covariates, HR for Q1 was 2.03 (95% CI 1.11-3.70; p-trend = 0.014). Sensitivity and subgroup analyses further confirmed a significant association between lower magnesium levels and a high risk of in-hospital mortality. Conclusions: Decreased serum magnesium levels at admission were independently associated with in-hospital mortality in AIS patients.

1.
Towfighi A, Tai W, Markovic D, Ovbiagele B: Sex-specific temporal trends in in-hospital mortality after stroke among middle-age individuals in the United States. Stroke 2011;42:2740-2745.
2.
Smith EE, Shobha N, Dai D, et al: Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program. Circulation 2010;122:1496-1504.
3.
Muir KW: Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness. CNS Drugs 2001;15:921-930.
4.
Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE: Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg 1996;85:117-124.
5.
Ascherio A, Rimm EB, Hernán MA, et al: Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 1998;98:1198-1204.
6.
Sluijs I, Czernichow S, Beulens JW, et al: Intakes of potassium, magnesium, and calcium and risk of stroke. Stroke 2014;45:1148-1150.
7.
Akarolo-Anthony SN, Jiménez MC, Chiuve SE, Spiegelman D, Willett WC, Rexrode KM: Plasma magnesium and risk of ischemic stroke among women. Stroke 2014;45:2881-2886.
8.
Larsson SC, Orsini N, Wolk A: Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. Am J Clin Nutr 2012;95:362-366.
9.
Ohira T, Peacock JM, Iso H, Chambless LE, Rosamond WD, Folsom AR: Serum and dietary magnesium and risk of ischemic stroke: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2009;169:1437-1444.
10.
Song Y, Li TY, van Dam RM, Manson JE, Hu FB: Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J Clin Nutr 2007;85:1068-1074.
11.
Gawaz M, Ott I, Reininger AJ, Neumann FJ: Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb Haemost 1994;72:912-918.
12.
Feng P, Niu X, Hu J, et al: Relationship of serum magnesium concentration to risk of short-term outcome of acute ischemic stroke. Blood Press 2013;22:297-301.
13.
Siegler JE, Boehme AK, Albright KC, et al: Acute decrease in serum magnesium level after ischemic stroke may not predict decrease in neurologic function. J Stroke Cerebrovasc Dis 2013;22:e516-e521.
14.
Bayir A, Ak A, Kara H, Sahin TK: Serum and cerebrospinal fluid magnesium levels, Glasgow Coma Scores, and in-hospital mortality in patients with acute stroke. Biol Trace Elem Res 2009;130:7-12.
15.
Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140.
16.
Teo BW, Xu H, Wang D, Li J, Sinha AK, Shuter B, et al: GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis 2011;58:56-63.
17.
Durrleman S, Simon R: Flexible regression models with cubic splines. Stat Med 1989;8:551-561.
18.
Muir KW, Lees KR, Ford I, Davis S: Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004;363:439-445.
19.
Saver JL, Starkman S, Eckstein M, et al: Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med 2015;372:528-536.
20.
Afshari D, Moradian N, Rezaei M: Evaluation of the intravenous magnesium sulfate effect in clinical improvement of patients with acute ischemic stroke. Clin Neurol Neurosurg 2013;115:400-404.
21.
Aslanyan S, Weir CJ, Muir KW, Lees KR: Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial. Stroke 2007;38:1269-1273.
22.
Jee SH, Miller ER 3rd, Guallar E, Singh VK, Appel LJ, Klag MJ: The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens 2002;15:691-696.
23.
Peacock JM, Folsom AR, Arnett DK, Eckfeldt JH, Szklo M: Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 1999;9:159-165.
24.
Simmons D, Joshi S, Shaw J: Hypomagnesaemia is associated with diabetes: not pre-diabetes, obesity or the metabolic syndrome. Diabetes Res Clin Pract 2010;87:261-266.
25.
Xu J, Xu W, Yao H, Sun W, Zhou Q, Cai L: Associations of serum and urinary magnesium with the pre-diabetes, diabetes and diabetic complications in the Chinese Northeast population. PLoS One 2013;8:e56750.
26.
Singla PN, Chand P, Kumar A, Kachhawaha JS: Serum magnesium levels in protein-energy malnutrition. J Trop Pediatr 1998;44:117-119.
27.
Van Laecke S, Nagler EV, Verbeke F, Van Biesen W, Vanholder R: Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 2013;126:825-831.
28.
Caso V, Agnelli G, Alberti A, et al: High diastolic blood pressure is a risk factor for in-hospital mortality in complete MCA stroke patients. Neurol Sci 2012;33:545-549.
29.
Abboud H, Labreuche J, Plouin F, Amarenco P: High blood pressure in early acute stroke: a sign of a poor outcome? J Hypertens 2006;24:381-386.
30.
Yong M, Kaste M: Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke 2008;39:2749-2755.
31.
Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001;32:2426-2432.
32.
Gomes F, Emery PW, Weekes CE: Risk of malnutrition is an independent predictor of mortality, length of hospital stay, and hospitalization costs in stroke patients. J Stroke Cerebrovasc Dis 2016;25:799-806.
33.
Ovbiagele B, Schwamm LH, Smith EE, et al: Patterns of care quality and prognosis among hospitalized ischemic stroke patients with chronic kidney disease. J Am Heart Assoc 2014;3:e000905.
34.
Chi OZ, Pollak P, Weiss HR: Effects of magnesium sulfate and nifedipine on regional cerebral blood flow during middle cerebral artery ligation in the rat. Arch Int Pharmacodyn Ther 1990;304:196-205.
35.
Kass IS, Cottrell JE, Chambers G: Magnesium and cobalt, not nimodipine, protect neurons against anoxic damage in the rat hippocampal slice. Anesthesiology 1988;69:710-715.
36.
Barbagallo M, Belvedere M, Dominguez LJ: Magnesium homeostasis and aging. Magnes Res 2009;22:235-246.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.